

1 **Systemic anticancer therapy for advanced renal cell** 2 **carcinoma: treatment options (favourable risk IMDC)**

3 Base all treatment choices on [shared decision making](#). Think about enrolment into a
4 clinical trial as an option at each step.

5 Initial recommended treatment options are the:

- 6 • [NICE technology appraisal guidance on avelumab with axitinib](#) (managed access
7 through the Cancer Drugs Fund) or
- 8 • [NICE technology appraisal guidance on sunitinib](#) or
- 9 • [NICE technology appraisal guidance on pazopanib](#) or
- 10 • [NICE technology appraisal guidance on tivozanib](#).

11 **Initial treatment with avelumab with axitinib**

12 For people who have disease progression after initial treatment in line with the [NICE](#)
13 [technology appraisal guidance on avelumab with axitinib](#) (managed access through
14 the Cancer Drugs Fund), recommended treatment options are the:

- 15 • [NICE technology appraisal guidance on cabozantinib](#) or
- 16 • [NICE technology appraisal guidance on lenvatinib with everolimus](#) or
- 17 • [NICE technology appraisal guidance on everolimus](#) or
- 18 • [NICE technology appraisal guidance on sunitinib](#) (NHS England Policy) or
- 19 • [NICE technology appraisal guidance on pazopanib](#) (NHS England Policy) or
- 20 • [NICE technology appraisal guidance on tivozanib](#) (NHS England Policy).

21 For people who have had initial treatment in line with the [NICE technology appraisal](#)
22 [guidance on avelumab with axitinib](#) (managed access through the Cancer Drugs
23 Fund) and have disease progression after treatment in line with the [NICE technology](#)
24 [appraisal guidance on cabozantinib](#), the only recommended treatment option is the
25 [NICE technology appraisal guidance on everolimus](#).

26 For people who have had initial treatment in line with the [NICE technology appraisal](#)
27 [guidance on avelumab with axitinib](#) (managed access through the Cancer Drugs
28 Fund) and have disease progression after treatment in line with the [NICE technology](#)

1 [appraisal guidance on lenvatinib with everolimus](#) or [everolimus](#), the only
2 recommended treatment option is the [NICE technology appraisal guidance on](#)
3 [cabozantinib](#).

4 For people who have had initial treatment in line with the [NICE technology appraisal](#)
5 [guidance on avelumab with axitinib](#) (managed access through the Cancer Drugs
6 Fund) and have disease progression after treatment in line with the [NICE technology](#)
7 [appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy),
8 recommended treatment options are the:

- 9 • [NICE technology appraisal guidance on cabozantinib](#) or
- 10 • [NICE technology appraisal guidance on everolimus](#).

11 For people who have had initial treatment in line with the [NICE technology appraisal](#)
12 [guidance on avelumab with axitinib](#) (managed access through the Cancer Drugs
13 Fund) who have disease progression after treatment in line with the [NICE technology](#)
14 [appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy) and
15 disease progression after treatment in line with the [NICE technology appraisal](#)
16 [guidance on cabozantinib](#), the only recommended treatment option is [NICE](#)
17 [technology appraisal guidance on everolimus](#).

18 For people who have had initial treatment in line with the [NICE technology appraisal](#)
19 [guidance on avelumab with axitinib](#) (managed access through the Cancer Drugs
20 Fund) who have disease progression after treatment in line with the [NICE technology](#)
21 [appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy) and
22 disease progression after treatment in line with the [NICE technology appraisal](#)
23 [guidance on everolimus](#), the only recommended treatment option is [NICE technology](#)
24 [appraisal guidance on cabozantinib](#).

25 **Initial treatment with sunitinib, pazopanib or tivozanib**

26 For people who have disease progression after initial treatment in line with the [NICE](#)
27 [technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#), recommended
28 treatment options are the:

- 29 • [NICE technology appraisal guidance on cabozantinib](#) or
- 30 • [NICE technology appraisal guidance on axitinib](#) or

- 1 • [NICE technology appraisal guidance on lenvatinib with everolimus](#) or
- 2 • [NICE technology appraisal guidance on everolimus](#) or
- 3 • [NICE technology appraisal guidance on nivolumab](#).

4 For people who have had initial treatment in line with the [NICE technology appraisal](#)
5 [guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) and have disease progression after
6 treatment in line with the [NICE technology appraisal guidance on cabozantinib](#),
7 recommended treatment options are the:

- 8 • [NICE technology appraisal guidance on everolimus](#) or
- 9 • [NICE technology appraisal guidance on nivolumab](#).

10 For people who have had initial treatment in line with the [NICE technology appraisal](#)
11 [guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) and have disease progression after
12 treatment in line with the [NICE technology appraisal guidance on axitinib](#),
13 recommended treatment options are the:

- 14 • [NICE technology appraisal guidance on cabozantinib](#) or
- 15 • [NICE technology appraisal guidance on everolimus](#) or
- 16 • [NICE technology appraisal guidance on nivolumab](#).

17 For people who have had initial treatment in line with the [NICE technology appraisal](#)
18 [guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) who have disease progression after
19 treatment in line with the [NICE technology appraisal guidance on axitinib](#) and
20 disease progression after treatment in line with the [NICE technology appraisal](#)
21 [guidance on cabozantinib](#), the only recommended treatment option is [NICE](#)
22 [technology appraisal guidance on everolimus](#).

23 For people who have had initial treatment in line with the [NICE technology appraisal](#)
24 [guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) who have disease progression after
25 treatment in line with the [NICE technology appraisal guidance on axitinib](#) and
26 disease progression after treatment in line with the [NICE technology appraisal](#)
27 [guidance on everolimus](#), the only recommended treatment option is [NICE technology](#)
28 [appraisal guidance on cabozantinib](#).

1 For people who have had initial treatment in line with the [NICE technology appraisal](#)
2 [guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) and who have disease progression
3 after treatment in line with the [NICE technology appraisal guidance on lenvatinib with](#)
4 [everolimus](#) or [everolimus](#), recommended treatment options are the:

- 5 • [NICE technology appraisal guidance on cabozantinib](#) or
- 6 • [NICE technology appraisal guidance on nivolumab](#).

7 For people who have had initial treatment in line with the [NICE technology appraisal](#)
8 [guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) and who have disease progression
9 after treatment in line with the [NICE technology appraisal guidance on nivolumab](#),
10 recommended treatment options are the:

- 11 • [NICE technology appraisal guidance on cabozantinib](#) or
- 12 • [NICE technology appraisal guidance on lenvatinib with everolimus](#).

13 For people who have had initial treatment in line with the [NICE technology appraisal](#)
14 [guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) who have disease progression after
15 treatment in line with the [NICE technology appraisal guidance on nivolumab](#) and
16 disease progression after treatment in line with the [NICE technology appraisal](#)
17 [guidance on cabozantinib](#), the only recommended treatment option is [NICE](#)
18 [technology appraisal guidance on everolimus](#).